Clinical trials: Depressed Mood
Major Depressive Disorder
A Dose Escalation Phase I Study of PDC-1421 Capsule Targeting in Depression
The purpose of this study is to evaluate the safety of PDC-1421 Capsule in healthy subject, find the effective adequate dose for the next stage of the study, and accumulate information of possible mechanism of its anti-depressive…
- Trial name
- NCT01774045
- Testing
- PDC-1421
- Where
- Taiwan
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- BioLite, Inc.
Bipolar Depression
Proof Of Mechanism Study To Determine Efficacy Of PF-04455242 In Blocking Spiradoline (PF-00345768) Stimulated Prolactin Release
This study will be a Proof of Mechanism (POM) study to establish evidence of central pharmacodynamic activity for PF 04455242, and will be a parallel group, randomized, double blind, sponsor open study conducted in healthy male…
- Trial name
- NCT00988949
- Testing
- PF-04455242, spiradoline
- Where
- Singapore
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depressive Disorder, Major, Unipolar Depression
Deep Brain Stimulation for Major Depressive Disorder
This study is designed as a prospective, multi-centered, double-blind, randomized, controlled 12-month pivotal study to evaluate the safety and efficacy of the ANS Libra® Deep Brain Stimulation System for patients with major…
- Trial name
- NCT00617162
- Testing
- Deep Brain Stimulation, Libra Deep Brain Stimulation System
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 125 people
- Sponsor
- Abbott Medical Devices
Major Depressive Disorder
Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder
The purpose of this study is to determine the efficacy and safety of once daily vortioxetine (Lu AA21004) in adults with major depressive disorder.
- Trial name
- NCT00672958
- Testing
- Vortioxetine
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 600 people
- Sponsor
- Takeda
Depressive Disorder, Major
An Eight-week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder
The main purpose of this study is to evaluate the efficacy of saredutant 100mg or 30mg once daily in combination with paroxetine 20mg once daily compared to saredutant placebo in combination with paroxetine 20mg once daily in…
- Trial name
- COMPASS (NCT00629551)
- Testing
- saredutant (SR48968), paroxetine
- Where
- 8 sites in United States, Chile and 6 more
- Volunteers
- 825 people
- Sponsor
- Sanofi
Postpartum Depression
A Study of BRII-297 in Healthy Adult Subjects
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of BRII-297 in healthy adult subjects.
- Trial name
- NCT05845840
- Testing
- BRII-297
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Anhedonia, Major Depressive Disorder
Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD
To evaluate the efficacy of NBI-1065846 compared with placebo on improving symptoms of anhedonia in participants with major depressive disorder (MDD).
- Trial name
- TERPSIS (NCT05165394)
- Testing
- NBI-1065846
- Where
- 23 sites in United States, Puerto Rico
- Volunteers
- 93 people
- Sponsor
- Neurocrine Biosciences
Depressive Episode, Depression
Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
The objective of this study is to collect data to finalize the development of MEB-001 software as a medical device. The data collected in this study will be used to develop MEB-001 machine learning algorithms by training the…
- Conditions
- Depressive Episode, Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- SAMDE (NCT05708222)
- Testing
- MEB-001
- Where
- 13 sites in United States
- Volunteers
- 715 people
- Sponsor
- Medibio Limited
Postpartum Depression
A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)
The purpose of this study was to determine if SAGE-547 Injection infused intravenously at up to 90 μg/kg/h for 60 hours reduces depressive symptoms in participants with moderate postpartum depression (PPD) compared to placebo…
- Trial name
- NCT02942017
- Testing
- SAGE-547 90 μg/kg/h
- Where
- 32 sites in United States
- Volunteers
- 108 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Bipolar, Bipolar Disorder (BD)
Transcranial Photobiomodulation for Bipolar Depression
This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression.
- Conditions
- Bipolar, Bipolar Disorder (BD), Bipolar Disorder Depression
- Trial name
- NCT07510646
- Testing
- Vielight Neuro Rx Gamma
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Vielight Inc.
Depression, Depressive Disorder
Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) Versus Placebo in Peri- and Postmenopausal Women
Desvenlafaxine succinate (DVS) is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI). The sustained-release (SR) formulation, DVS SR, is being studied in the development program for the treatment of…
- Conditions
- Depression, Depressive Disorder, Depressive Disorder, Major
- Trial name
- NCT00369343
- Testing
- Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)
- Where
- 37 sites in United States
- Volunteers
- 381 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Major Depressive Disorder, Major Depressive Episode
Mobile Observation Of Depression
The primary aim of this project is to test if OCOsense glasses can function as a digital phenotyping tool derived from behavioural and physiological signals related to facial expression and motion recorded using the glasses.
- Conditions
- Major Depressive Disorder, Major Depressive Episode, Bipolar Disorder
- Trial name
- MOOD (NCT05815459)
- Testing
- OCOsense
- Where
- United Kingdom
- Volunteers
- 84 people
- Sponsor
- Emteq Ltd